Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Global Migraine Drugs Market by Application (Injection, Oral) by Types (Preventive Medicine, Abortive Medicine) – Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

Global Migraine Drugs Market was valued at USD XX Billion in the year 2017. Global Migraine Drugs Market is further estimated to grow at a CAGR of XX% from 2018 to reach USD XX Billion by the year 2023. North America region holds the highest market share in 2017 and Asia-Pacific is considered as the fastest growing market in the forecasted period. At a country level, developed markets like the U.S holds the notable market share in 2017 and it is projected to grow at a gradual rate in the coming years.

Endo International Plc. (U.S), Abbott (U.S), Johnson & Johnson Services, Inc. (U.S), Pfizer Inc. (U.S), Allergan Plc. (Dublin), Eisai Co., Ltd. (Japan), AbbVie Inc. (U.S), GlaxoSmithKline Plc. (U.K), Merck & Co., Inc. (U.S), AstraZeneca PLC (U.K), are some of the key players in the Migraine Drugs Market.

Drivers:

Increase in alertness among patients

Restraints:

Side effects of migraine drugs

Opportunities:

Developing migraine therapies

Challenges:

Availability of raw materials  

Segmentation done on the basis of Type includes Preventive Medicine and Abortive Medicine of which the Abortive Medicine segment is expected to hold the highest market share during the forecast period. On the other hand, segmentation done on the basis of Application includes Injection and Oral of which Oral segment is expected to grow at the highest CAGR during the forecast period.

Key Benefits for Stakeholders

Migraine Drugs Market manufacturers, dealers and suppliers

Migraine disease associations

Pharmaceutical and R&D laboratories,

Research and consulting firms.

By Application

Injection

Oral

Others

By Types

Preventive Medicine

     Beta Blocker

     Anticonvulsant

     Antidepressant

     Others

Abortive Medicine

     Ergotamine Derivative

     Triptans

     Others

By Distribution

Online Pharmacies

Retail Pharmacies

Hospital-based Pharmacies

By Region

North America

Europe

Asia-Pacific

ROW

Key Market Players

Endo International Plc.

Abbott

Johnson & Johnson Services, Inc.

Pfizer Inc.

Allergan Plc.

Eisai Co., Ltd.

AbbVie Inc.

GlaxoSmithKline Plc.

Merck & Co., Inc.

AstraZeneca PLC

(Another brief information of 10 companies will provided in report)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1.      Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2.      Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3.      To avoid bias, we filter the collected data collected from authenticated sources.
  4.      GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5.      Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.

Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottom-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Migraine Drugs Market, By Application

6.1. Injection

6.2. Oral

6.3. Others

7. Migraine Drugs Market, By Types

7.1. Preventive Medicine

       7.1.1. Beta Blocker

       7.1.2. Anticonvulsant

       7.1.3. Antidepressant

       7.1.4. Others

7.2. Abortive Medicine

       7.2.1. Ergotamine Derivative

       7.2.2. Triptans

       7.2.3. Others

8. Migraine Drugs Market, By Distribution

8.1. Online Pharmacies

8.2. Retail Pharmacies

8.3. Hospital-based Pharmacies

9. Geographical Analysis

9.1. Introduction

9.2. North America

       9.2.1. U.S.

       9.2.2. Canada

       9.2.3. Mexico

9.3. Europe

       9.3.1. U.K.

       9.3.2. Germany

       9.3.3. Russia

       9.3.4. RoE

9.4. Asia Pacific

       9.4.1. China

       9.4.2. Japan

       9.4.3. India

       9.4.4. RoAPAC

9.5. RoW

       9.5.1. Latin America

       9.5.2. Middle East and Africa

10. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

10.1 Endo International Plc.

10.2. Abbott

10.3. Johnson & Johnson Services, Inc.

10.4. Pfizer Inc.

10.5. Allergan Plc.

10.6. Eisai Co., Ltd.

10.7. AbbVie Inc.

10.8. GlaxoSmithKline Plc.

10.9. Merck & Co., Inc.

10.10. AstraZeneca PLC

(Another brief information of 10 companies will be provided in the report)

11. Competitive Analysis

11.1. Introduction

11.2. Market Positioning of Key Players

11.3 Competitive Strategies Adopted by Leading Players

        11.3.1. Investments & Expansions

        11.3.2. New Product Launches

        11.3.3. Mergers & Acquisitions

        1.3.4. Agreements, Joint Ventures, and Partnerships

12. Appendix

12.1. Questionnaire

12.2. Available Customizations 

12.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

* The list of tables and figures will be provided in the sample report

Summary

No Content Available.

PURCHASE OPTIONS

ASK FOR SPECIAL PRICING

Related Reports